Loading…
Loading…
Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab's FDA approval. Zanidatamab's first-line HER2+ gastroesophageal cancer approval expands the eligible patient population and unlocks a $250M milestone plus 10–20% tiered royalties. ZYME's near-term upside hinges on commercial execution, label expansions, and integrating durable cash-flow assets like YUPELRI from the pending Theravance acquisition.
Bank of America Corp DE lifted its stake in Zymeworks Inc. (NASDAQ: ZYME) by 164.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 236,754 shares of the company's stock after buying an additional 147,230 shares during the period. Bank
Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.
Deutsche Bank AG purchased a new stake in Zymeworks Inc. (NASDAQ: ZYME) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 397,190 shares of the company's stock, valued at approximately $10,383,000. Deutsche Bank AG owned approximately 0.54% of
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to earnings of $0.03 per share a year ago.
August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190 million in potential additional global regulatory milestones Acquisition of Theravance Biopharma, Inc. expected to close in 2H 2026, adding durable commercial cash flows and expanding Zymeworks' diversified revenue base Continued advancement of R&D pipeline across wholly-owned and partnered programs Repurchased $49.4 million of common shares as of August 4, 2026 under the newly authorized 2026 share repurchase program Strong balance sheet with $322.5 million in cash, cash equivalents and marketable securities as of June 30, 2026 VANCOUVER, British Columbia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today reported financial results for the second quarter ended June 30, 2026 and provided a summary of recent business highlights. In light of the previously announced proposed acquisition of Theravance Biopharma, the Company has elected not to host a second quarter earnings conference call after release of its financial results.
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026.